These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 32906729)

  • 1. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.
    Khamaisi H; Mahmoud H; Mahajna J
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
    Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
    Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
    PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
    PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
    Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
    Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings.
    Tossetta G
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
    Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
    Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
    Calo CA; Smith BQ; Dorayappan KDP; Saini U; Lightfoot M; Wagner V; Kalaiyarasan D; Cosgrove C; Wang QE; Maxwell GL; Kálai T; Kuppusamy P; Cohn DE; Selvendiran K
    Gynecol Oncol; 2022 Jan; 164(1):136-145. PubMed ID: 34756749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
    Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
    Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel.
    Seino M; Okada M; Sakaki H; Takeda H; Watarai H; Suzuki S; Seino S; Kuramoto K; Ohta T; Nagase S; Kurachi H; Kitanaka C
    Oncol Rep; 2016 Jan; 35(1):593-601. PubMed ID: 26534836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
    Nonaka M; Itamochi H; Kawaguchi W; Kudoh A; Sato S; Uegaki K; Naniwa J; Sato S; Shimada M; Oishi T; Terakawa N; Kigawa J; Harada T
    Int J Gynecol Cancer; 2012 Jul; 22(6):922-9. PubMed ID: 22672985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.
    Atwani R; Nagare RP; Rogers A; Prasad M; Lazar V; Sandusky G; Tong Y; Pin F; Condello S
    J Exp Clin Cancer Res; 2024 Jun; 43(1):156. PubMed ID: 38822429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epithelial ovarian cancer].
    Hilpert F; Krause G; Venhoff L; Kühnle E; Schem C; Maass N
    Ther Umsch; 2007 Jul; 64(7):375-80. PubMed ID: 17948754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.